Torrent Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹4,197Cr
- +41.8% YoY
- +27.1% QoQ
- Net profit
- ₹364Cr
- −26.9% YoY
- −42.7% QoQ
- Margin
- 32%
- −1 pp YoY
- −1 pp QoQ
Guidance rank: #57 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).
From Torrent Pharma.'s Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023.
- India base business (excluding JB) grew 15% in Q4 FY26, expected to deliver mid-teens growth in FY27, barring external demand shocks.
- Curatio business grew 27% in FY26, with strong outlook for continued traction driven by OTC advertising and field force expansion.
- Brazil market projected to grow 10-15% CAGR over FY26-27 driven by new launches and price increases.
- US business grew 31% INR growth in FY26, with expected single-digit growth on the back of single-digit product launches in FY27.
- JB Pharma salesforce attrition improved; integration expected to enhance revenue synergies over next 2-3 years.
2 more points from Torrent Pharma.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Torrent Pharma. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).
- There is interest in in-licensing products, especially from China and other markets, to expand opportunities in India (Page 6).
- For the Semaglutide injectable business in India, potential future manufacturing in-house is considered if the product scales significantly (Page 14).
2 more points from Torrent Pharma.'s call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Torrent Pharma. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Torrent Pharma.'s call on order book
Create a free account to keep reading this call
Torrent Pharma. — Quarterly revenue & net profit
Torrent Pharma. Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 4,197 | 2,959 | +41.8% | 3,303 | +27.1% |
| Operating profit (EBITDA) | 1,356 | 964 | +40.7% | 1,088 | +24.6% |
| Operating margin | 32% | 33% | -1 pp | 33% | -1 pp |
| Profit before tax | 529 | 665 | -20.5% | 814 | -35% |
| Net profit (PAT) | 364 | 498 | -26.9% | 635 | -42.7% |
| EPS (₹) | 10.76 | 14.71 | -26.9% | 18.76 | -42.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹5.0K Cr, net profit ₹534 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Torrent Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Torrent Pharma. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Torrent Pharma. Q4 FY26 results?
Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).
What is Torrent Pharma. share price analysis?
Torrent Pharma. currently shows a neutral. The stock trades at a P/E of 83.5 with a market cap of ₹186,247 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharma. planning capital expenditure?
Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).
Keep Torrent Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
